Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Tesmilifene: YM began Phase II testing of Tesmilifine in combination with chemotherapy in 24 patients with hormone refractory metastatic prostate cancer in the

YM Biosciences Inc., Mississauga, Ontario
Product: Tesmilifene

Read the full 76 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE